title: Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin.
abstract: Retinoids exert their biologic effects through two families of nuclear receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which belong to the superfamily of steroid/thyroid hormone nuclear receptors. By using a subtraction hybridization approach, we have identified a cDNA sequence TIG2 (Tazarotene-induced gene 2), whose expression is up-regulated by the treatment of skin raft cultures by an RAR beta/gamma-selective anti-psoriatic synthetic retinoid tazarotene [AGN 190168/ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)-ethynyl] nicotinate]. The retinoid-mediated up-regulation in the expression of TIG2 was confirmed by Northern blot analysis. Upon sequencing, TIG2 was found to be a cDNA whose complete sequence was not in the GenBank and EMBL data bases. The TIG2 cDNA is 830 bp long and encodes a putative protein product of 164 amino acids. TIG2 is neither expressed nor induced by tazarotene in primary keratinocyte and fibroblast cultures. Thus, TIG2 is expressed and induced by tazarotene only when keratinocytes and fibroblasts form a tissue-like 3-dimensional structure. We further demonstrate that RAR-specific retinoids increase TIG2 mRNA levels. In contrast, neither RXR-specific retinoids nor 1,25-dihydroxyvitamin D3 increased TIG2 levels. Finally, we demonstrate that TIG2 is expressed at high levels in nonlesional psoriatic skin but at lower levels in the psoriatic lesion and that its expression is up-regulated in psoriatic lesions after topical application of tazarotene.
authors.affiliation: Department of Biology, Allergan, Inc., Irvine, California 92713, U.S.A.
authors.forename: S
authors.initials: S
authors.lastname: Nagpal
authors.forename: S
authors.initials: S
authors.lastname: Patel
authors.forename: H
authors.initials: H
authors.lastname: Jacobe
authors.forename: D
authors.initials: D
authors.lastname: DiSepio
authors.forename: C
authors.initials: C
authors.lastname: Ghosn
authors.forename: M
authors.initials: M
authors.lastname: Malhotra
authors.forename: M
authors.initials: M
authors.lastname: Teng
authors.forename: M
authors.initials: M
authors.lastname: Duvic
authors.forename: R A
authors.initials: RA
authors.lastname: Chandraratna
mesh_terms: D000287:Administration, Topical; D000595:Amino Acid Sequence; D001483:Base Sequence; D002117:Calcitriol / Q000494:pharmacology; D002478:Cells, Cultured; D002874:Chromosome Mapping; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D018076:DNA, Complementary / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D008969:Molecular Sequence Data; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000235:genetics*; D011565:Psoriasis / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000235:genetics / Q000502:physiology; D047488:Retinoid X Receptors; D012689:Sequence Homology, Nucleic Acid; D012867:Skin / Q000166:cytology; D012879:Skin Physiological Phenomena; D014157:Transcription Factors / Q000235:genetics / Q000502:physiology; D015854:Up-Regulation; D012176:Retinoids
chemical_list: D002117:Calcitriol; D018076:DNA, Complementary; D009539:Nicotinic Acids; D012333:RNA, Messenger; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D014157:Transcription Factors; C086827:tazarotene; D012176:Retinoids